Spina E, Birgersson C, von Bahr C, Ericsson O, Mellström B, Steiner E, Sjöqvist F
Clin Pharmacol Ther. 1984 Nov;36(5):677-82. doi: 10.1038/clpt.1984.239.
The 2-hydroxylation of desmethylimipramine (DMI) and the 4-hydroxylation of debrisoquine (D) were studied in healthy subjects and in human liver microsomes. A single oral dose of DMI (25 mg) was given to 18 healthy subjects previously phenotyped with D (13 rapid and five slow hydroxylators). Urine was collected for 24 hr and DMI and total 2-hydroxydesmethylimipramine (2-OH-DMI) levels were determined by HPLC. The urinary ratio DMI/2-OH-DMI correlated strongly (r = 0.92) with the urinary ratio of D to 4-hydroxydebrisoquine (D/4-OH-D). The two hydroxylations were also studied in human liver microsomes from 10 different subjects. Formation rates of the hydroxylated metabolites correlated strongly (r = 0.869). Moreover, D competitively inhibited the 2-hydroxylation of DMI. These findings suggest that both are hydroxylated by the same cytochrome P-450 isozyme.
在健康受试者和人肝微粒体中研究了去甲丙咪嗪(DMI)的2-羟基化作用以及异喹胍(D)的4-羟基化作用。给18名先前已用D进行表型分析的健康受试者(13名快速羟化者和5名慢速羟化者)口服单次剂量的DMI(25毫克)。收集24小时尿液,通过高效液相色谱法测定DMI和总2-羟基去甲丙咪嗪(2-OH-DMI)水平。尿中DMI/2-OH-DMI比值与尿中D与4-羟基异喹胍的比值(D/4-OH-D)密切相关(r = 0.92)。还在来自10名不同受试者的人肝微粒体中研究了这两种羟基化作用。羟基化代谢产物的生成速率密切相关(r = 0.869)。此外,D竞争性抑制DMI的2-羟基化作用。这些发现表明二者均由同一种细胞色素P-450同工酶进行羟基化。